1790s

1790s

1800s

1800s

1810s

1810s

1820s

1820s

1830s

1830s

1840s

1840s

1850s

1850s

1860s

1860s

1870s

1870s

1880s

1880s

1890s

1890s

1900s

1900s

1910s

1910s

1920s

1920s

1930s

1930s

1940s

1940s

1950s

1950s

1960s

1960s

1970s

1970s

1980s

1980s

1990s

1990s

2000s

2000s

2010s

2010s

Timelines: 1989

Prev : Next Vascular endothelial growth factor (VEGF)


Napoleone Ferrara

Trying to starve tumors

Genentech molecular biologist Napoleone Ferrara leads a team that characterizes VEGF (vascular endothelial growth factor), a molecule with pro-angiogenic properties. Angiogenesis refers to the growth of blood vessel networks. Ferrara’s discovery leads to the development of Avastin® (bevacizumab, rhuMAb-VEGF). Avastin is a recombinantly-humanized monoclonal antibody that interferes with angiogenic processes. It is approved in 2004 for the treatment of metastatic colorectal cancer, and later for non-small cell lung cancer, HER2-negative breast cancer, glioblastoma, and renal cell carcinoma.   

 


 
You have clicked on a link that will take you to another website. Click here to continue and leave the Life Sciences Foundation website.
Close